Vildagliptin
DPP4 inhibitor / A potent inhibitor of dipeptidyl peptidase IV (DPP IV), an enzyme that cleaves glucagon-like peptide 1 (GLP-1)1. Delaying the degradation of GLP-1 extends the action of insulin and suppressing the release of glucagon which results in reduction in elevated blood glucose levels (hyperglycemia)2. Clinically useful antidiabetic agent. Ameliorates cognitive deficits in streptozotocin-induced Alzheimers disease model3. Displays protective effects on β-cells by inhibition of ER stress in a mouse model4.
Biochemicals & reagents
274901-16-5
LAF237
1) Balas et al. (2007), the dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients; J. Clin. Endocrinol. Metab., 92 1249 2) Ahren et al. (2004), Inhibition od dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes J. Clin. Emdocrinol. Metab., 89 2078 3) Kosaraju et al. (2013), Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s disease; J. Pharm. Pharmacol., 65 1773 4) Shimizu et al. (2012), DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice; J. Mol. Endocrinol., 49 125
-20°C
TARGET: Protease -- PATHWAY: Carbohydrate metabolism -- RESEARCH AREA: Cellular stress; Neuroscience -- DISEASE AREA: Diabetes; Neurodegeneration